ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Dextroamphetamine (Dexamphetamine). Safety and efficacy of dextroamphetamine pharmacotherapy for women who are pregnant have not been established. Studies to date on the use of dextroamphetamine during the first trimester of pregnancy have provided mixed results in relation to congenital malformations and, thus, are inconclusive. Safety and efficacy of dextroamphetamine pharmacotherapy for women who are breast-feeding and their neonates and infants have not been established. Amphetamines are excreted in breast milk. Expected pharmacologic actions may be observed among breast-fed neonates and infants, who also may become addicted. Decrements in predicted growth have been associated with long-term dextroamphetamine pharmacotherapy among children. Avoid prescribing dextroamphetamine pharmacotherapy to women who are pregnant. If dextroamphetamine pharmacotherapy is required, advise patients of potential benefits and possible risks to themselves and the embryo, fetus, or neonate.
